Search - tctmd.com

Displaying 141 - 160 of 378

Sort: Relevancy | Date

Presentation TCT 2017

Keynote Lecture: A Brief 40-Year History of PCI - How Far We've Come, How Far We Have to Go

Presenter: Dean J. Kereiakes, Spencer B. King III, Robert A. Byrne

October 30, 2017

Presentation iASSESS 2017

New Generation Drug Eluting Stents & Bioabsorbable Vascular Scaffolds: Indications, Outcomes, & Complications

Presenter: Rajesh V. Swaminathan, Dmitriy N. Feldman

August 30, 2017

Presentation Fellows 2017

The Evolution of Drug-Eluting Stents

Presenter: Ajay J. Kirtane

April 07, 2017

Presentation

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

February 13, 2017

Presentation TCT 2016

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at Three Months and Neoatherosclerosis at Eighteen Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Giulio Guagliumi

November 02, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Presenter: Philip M. Urban, Stephen G. Worthley, Bonnie H. Weiner

November 01, 2016

Presentation TCT 2016

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Stephen G. Ellis

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Robert-Jan van Geuns

November 01, 2016

Presentation TCT 2016

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Dmitriy N. Feldman, Emmanouil S. Brilakis

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Presenter: Philip M. Urban, Stephen G. Worthley, Christian M. Spaulding

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

Presenter: Philip M. Urban, Stephen G. Worthley, Sigmund Silber

November 01, 2016

Presentation TCT 2016

TCT 313: Incidence and Predictors of Very Late Major Adverse Cardiac Events After Metallic Stents: A Patient-Level Pooled Analysis from Seventeen Randomized Trials

Presenter: Serban Puricel, Clemens von Birgelen

November 01, 2016

Presentation TCT 2016

TCT 263: Impact of Diabetes on Clinical Outcomes in Patients Undergoing Unprotected Left Main Percutaneous Coronary Intervention with Drug-Eluting Stents

Presenter: Kevin J. Beatt, Frederick Feit

October 31, 2016

Presentation TCT 2016

Self-Expanding Stentys Stent In Various Anatomic Subsets: Evidence Of Clinical Benefit?

Presenter: Chaim S. Lotan, Giora Weisz, Francesco Prati

October 31, 2016

Presentation TCT 2016

Acute MI/SVGS/Thrombus Containing Lesions: Mesh-Covered Mguard Prime

Presenter: Chaim S. Lotan, Giora Weisz

October 31, 2016

Presentation TCT 2016

Small Vessels: Svelte Stent On A Wire

Presenter: Chaim S. Lotan, Giora Weisz, Jordan Safirstein

October 31, 2016

Presentation TCT 2016

Bifurcation/Left Main Stents IV: Nile

Presenter: Chaim S. Lotan, Giora Weisz, Ivo Petrov

October 31, 2016

Presentation TCT 2016

Bifurcation/Left Main Stents III: Bioss

Presenter: Chaim S. Lotan, Giora Weisz, Robert J. Gil

October 31, 2016

Presentation TCT 2016

DELTA 2: A Prospective, Multicenter Registry Evaluating New Generation Drug-Eluting Stents in Patients with Obstructive Left Main Coronary Artery Disease

Presenter: Thomas F. Luscher, Patrick W. Serruys, Alaide Chieffo

October 31, 2016

Presentation TCT 2016

Bifurcation/Left Main Stents II: Axxess

Presenter: Chaim S. Lotan, Giora Weisz, Christophe Dubois

October 31, 2016

Advertisement

Keynote Lecture: A Brief 40-Year History of PCI - How Far We've Come, How Far We Have to Go

New Generation Drug Eluting Stents & Bioabsorbable Vascular Scaffolds: Indications, Outcomes, & Complications

The Evolution of Drug-Eluting Stents

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at Three Months and Neoatherosclerosis at Eighteen Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

TCT 313: Incidence and Predictors of Very Late Major Adverse Cardiac Events After Metallic Stents: A Patient-Level Pooled Analysis from Seventeen Randomized Trials

TCT 263: Impact of Diabetes on Clinical Outcomes in Patients Undergoing Unprotected Left Main Percutaneous Coronary Intervention with Drug-Eluting Stents

Self-Expanding Stentys Stent In Various Anatomic Subsets: Evidence Of Clinical Benefit?

Acute MI/SVGS/Thrombus Containing Lesions: Mesh-Covered Mguard Prime

Small Vessels: Svelte Stent On A Wire

Bifurcation/Left Main Stents IV: Nile

Bifurcation/Left Main Stents III: Bioss

DELTA 2: A Prospective, Multicenter Registry Evaluating New Generation Drug-Eluting Stents in Patients with Obstructive Left Main Coronary Artery Disease

Bifurcation/Left Main Stents II: Axxess

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content